Log in

Relevant bibliographies by topics / 61:658.011.56(0432) / Journal articles

To see the other types of publications on this topic, follow the link: 61:658.011.56(0432).

Journal articles on the topic '61:658.011.56(0432)'

Author: Grafiati

Published: 30 May 2022

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 33 journal articles for your research on the topic '61:658.011.56(0432).'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Fares-Otero, N. E., B. Solé, S. Martin-Parra, et al. "Mindfulness, Attention, and Impulsivity in Bipolar Disorder." European Psychiatry 66, S1 (2023): S84—S85. http://dx.doi.org/10.1192/j.eurpsy.2023.262.

Full text

Abstract:

IntroductionBipolar disorder (BD) is a chronic mental disorder characterized by mood instability1. BD is further related to neurocognitive and functional disruptions that remain remarkably stable even when patients are euthymic, leading to poor well-being and quality of life. Mindfulness means paying attention on purpose, in the present moment, and involves different facets such as observing, describing, acting with awareness, non-judging and non-reacting of inner experience. It remains unclear whether mindfulness and its specific facets are differentially associated with different aspects of

APA, Harvard, Vancouver, ISO, and other styles

2

Lee, Megan, Molly Schiffer, Iris Isufi, et al. "Weekly Dosing Schedule of Brentuximab Vedotin in Mycosis Fungoides/Sezary Syndrome and Aggressive T Cell Lymphomas." Blood 136, Supplement 1 (2020): 21–22. http://dx.doi.org/10.1182/blood-2020-139790.

Full text

Abstract:

Introduction While the approved dose of brentuximab in T cell lymphomas has been every 3 weeks on a 1.8 mg/kg schedule, earlier studies exploring weekly dosing showed that a dose of 1.2 mg/kg on a weekly dosing (every 3 out of 4 weeks) in pts with Hodgkin's lymphoma and hematologic malignancies may improve cancer response rates while still having manageable side effects3. We explored the weekly dosing schedule in 37 pts (pts) with mycosis fungoides/Sezary syndrome (MF/SS) and aggressive T cell lymphomas and compared to our experience with every 3 week dosing in 36 pts to evaluate tolerability

APA, Harvard, Vancouver, ISO, and other styles

3

Costa, Bruno Marques, Paulo Ferreira, Sandra Costa, et al. "Association between Functional EGF+61 Polymorphism and Glioma Risk." Clinical Cancer Research 13, no. 9 (2007): 2621–26. http://dx.doi.org/10.1158/1078-0432.ccr-06-2606.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Jardim, Denis L., Kenneth R. Hess, Patricia LoRusso, Razelle Kurzrock, and David S. Hong. "Predictive Value of Phase I Trials for Safety in Later Trials and Final Approved Dose: Analysis of 61 Approved Cancer Drugs." Clinical Cancer Research 20, no. 2 (2013): 281–88. http://dx.doi.org/10.1158/1078-0432.ccr-13-2103.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Cleary, James M., Victoria Wang, Rebecca S. Heist, et al. "Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors." Clinical Cancer Research 27, no. 11 (2021): 2996–3004. http://dx.doi.org/10.1158/1078-0432.ccr-21-0066.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Arend, Rebecca C., Carly B. Scalise, Emily R. Gordon, et al. "Metabolic Alterations and WNT Signaling Impact Immune Response in HGSOC." Clinical Cancer Research 28, no. 7 (2022): 1433–45. http://dx.doi.org/10.1158/1078-0432.ccr-21-2984.

Full text

Abstract:

Abstract Purpose: Our study used transcriptomic and metabolomic strategies to determine the molecular profiles of HGSOC patient samples derived from primary tumor and ascites cells. These data identified clinically relevant heterogeneity among and within patients and highlighted global and patient-specific cellular responses to neoadjuvant chemotherapy (NACT). Experimental Design: Tissue from 61 treatment-naïve patients with HGSOC were collected. In addition, 11 benign, 32 ascites, and 18 post-NACT samples (matched to the individual patient's pre-NACT sample) were collected. RNA sequencing (RN

APA, Harvard, Vancouver, ISO, and other styles

7

Wesseling, Jelle. "Abstract F1-2: Clonal evolution of DCIS to invasion." Cancer Research 83, no. 5_Supplement (2023): F1–2—F1–2. http://dx.doi.org/10.1158/1538-7445.sabcs22-f1-2.

Full text

Abstract:

Abstract Clonal evolution of DCIS to invasion Ductal carcinoma in situ (DCIS) is the most common form of preinvasive breast cancer and, despite treatment, a small fraction (5-10%) of DCIS patients develop subsequent invasive breast cancer (IBC). If not treated, at least 3 out of 4 women with DCIS will not develop IBC1-3. This implies many women with non-progressive, low-risk DCIS are likely to carry the burden of overtreatment. To solve this DCIS dilemma, two fundamental questions need to be answered. The first question is, how the subsequent IBC is related to the initial DCIS lesion. The seco

APA, Harvard, Vancouver, ISO, and other styles

8

Else, Tobias, Eric Jonasch, Othon lliopoulos, et al. "Belzutifan for von Hippel-Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study." Clinical Cancer Research, February 23, 2024. http://dx.doi.org/10.1158/1078-0432.ccr-23-2592.

Full text

Abstract:

Abstract Purpose: Primary analysis of the ongoing, single-arm, phase 2 LITESPARK-004 study (NCT03401788) showed clinically meaningful antitumor activity in von Hippel-Lindau (VHL) disease–associated renal cell carcinoma (RCC) and other neoplasms with belzutifan treatment. We describe results of belzutifan treatment for VHL disease-associated pancreatic lesions (pancreatic neuroendocrine tumors [pNETs] and serous cystadenomas). Patients and Methods: Adults with VHL diagnosis based on germline VHL alteration, ≥1 measurable RCC tumor, no renal tumor &gt;3 cm or other VHL neoplasm requiring im

APA, Harvard, Vancouver, ISO, and other styles

9

Allan, John N., Ian W. Flinn, Tanya Siddiqi, et al. "Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia." Clinical Cancer Research, June 7, 2023, OF1—OF9. http://dx.doi.org/10.1158/1078-0432.ccr-22-2779.

Full text

Abstract:

Abstract Purpose: The CAPTIVATE study investigated first-line ibrutinib plus venetoclax for chronic lymphocytic leukemia in 2 cohorts: minimal residual disease (MRD)-guided randomized discontinuation (MRD cohort) and Fixed Duration (FD cohort). We report outcomes of fixed-duration ibrutinib plus venetoclax in patients with high-risk genomic features [del(17p), TP53 mutation, and/or unmutated immunoglobulin heavy chain (IGHV)] in CAPTIVATE. Patients and Methods: Patients received three cycles of ibrutinib 420 mg/day then 12 cycles of ibrutinib plus venetoclax (5-week ramp-up to 400 mg/day). FD

APA, Harvard, Vancouver, ISO, and other styles

10

Patel, Timil H., Amy Corneli, Pamela Balcazar, et al. "Adoption of Decentralized Trial Elements in Cancer Clinical Trials Supporting FDA Approvals During COVID-19." Clinical Cancer Research, March 4, 2025. https://doi.org/10.1158/1078-0432.ccr-24-3357.

Full text

Abstract:

Abstract The COVID-19 pandemic disrupted cancer clinical trials, prompting sponsors to adopt decentralized clinical trial (DCT) elements to ensure patient safety and trial continuity. Supported by FDA emergency guidance, the FDA Oncology Center of Excellence, in collaboration with the Clinical Trials Transformation Initiative (CTTI), conducted an assessment of DCT elements in cancer trials leading to FDA approval during the pandemic. Between December 6, 2022, and January 17, 2023, CTTI collected survey data from trial sponsors about DCT elements used in response to the pandemic, implementation

APA, Harvard, Vancouver, ISO, and other styles

11

Fallah, Jaleh, Michael H. Brave, Chana Weinstock, et al. "FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease–Associated Tumors." Clinical Cancer Research, July 1, 2022, OF1. http://dx.doi.org/10.1158/1078-0432.ccr-22-1054.

Full text

Abstract:

Abstract On August 13, 2021, the FDA approved belzutifan (WELIREG, Merck), a first-in-class hypoxia-inducible factor (HIF) inhibitor for adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery. The FDA granted approval based on the clinically meaningful effects on overall response rate (ORR) observed in patients enrolled in Study MK-6482-004. All 61 patients had VHL-associated RCC; some also had CNS hemangioblasto

APA, Harvard, Vancouver, ISO, and other styles

12

Monfrini, Chiara, Federico Stella, Vanessa Aragona, et al. "Phenotypic composition of commercial anti-CD19 CAR-T cells affects in vivo expansion and disease response in large B-cell lymphoma patients." Clinical Cancer Research, May 18, 2022. http://dx.doi.org/10.1158/1078-0432.ccr-22-0164.

Full text

Abstract:

Abstract Background: In clinical trials, the expansion and persistence of CAR-T cells correlate with therapeutic efficacy. However, properties of CAR-T cells that enable their in vivo proliferation have still to be consistently defined and the role of CAR-T bag content has never been investigated in a real life setting. Experimental Design: Residual cells obtained after washing 61 anti-CD19 CAR-T product bags were analysed to identify tisagenlecleucel/Tisa-cel and axicabtagene ciloleucel/Axi-cel phenotypic features associated with post-infusion CAR-T cell in vivo expansion and with response an

APA, Harvard, Vancouver, ISO, and other styles

13

Pypa, Larysa, and Maryna Murhina. "Laboratory changes and levels of biomarkers in localized bacterial infections and sepsis in children." August 28, 2017. https://doi.org/10.5281/zenodo.885397.

Full text

Abstract:

Pypa Larysa, Murhina Maryna. Laboratory changes and levels of biomarkers in localized bacterial infections and sepsis in children. Journal of Education, Health and Sport. 2017;7(8):701-711. eISSN 2391-8306. DOI http://dx.doi.org/10.5281/zenodo.885397 http://ojs.ukw.edu.pl/index.php/johs/article/view/4779 The journal has had 7 points in Ministry of Science and Higher Education parametric evaluation. Part B item 1223 (26.01.2017). 1223 Journal of Education, Health and Sport eISSN 2391-8306 7 © The Authors 2017; This article is published with open access at Licensee Open Journal Systems of Kazimi

APA, Harvard, Vancouver, ISO, and other styles

14

Lee, Sunyoung, Rachna T. Shroff, Shalini Makawita, et al. "Phase II Study of Ramucirumab in Advanced Biliary Tract Cancer Previously Treated By Gemcitabine-Based Chemotherapy." Clinical Cancer Research, April 14, 2022, OF1—OF8. http://dx.doi.org/10.1158/1078-0432.ccr-21-3548.

Full text

Abstract:

Abstract Purpose: VEGF receptor-2 (VEGFR-2)–mediated angiogenesis contributes to pathogenesis of biliary tract cancers (BTC). We investigated ramucirumab, a mAb targeting VEGFR-2 for treatment of advanced, chemorefractory BTC. Experimental Design: This is a phase II, single-arm trial for advanced, unresectable, pre-treated patients with BTC with ECOG 0/1, adequate liver, renal, and marrow functions. Ramucirumab was administered at 8 mg/kg, 2 weekly with restaging performed 8 weekly. Primary endpoint was progression-free survival (PFS). Secondary endpoints were overall response rate (ORR), dise

APA, Harvard, Vancouver, ISO, and other styles

15

Desai, Pinkal, Sagar Lonial, Amanda Cashen, et al. "A PHASE 1 FIRST-IN-HUMAN STUDY OF THE MCL-1 INHIBITOR AZD5991 IN PATIENTS WITH RELAPSED/REFRACTORY HEMATOLOGIC MALIGNANCIES." Clinical Cancer Research, August 21, 2024. http://dx.doi.org/10.1158/1078-0432.ccr-24-0028.

Full text

Abstract:

Abstract Background: AZD5991, a human MCL-1 inhibitor, was assessed for safety, tolerability, pharmacokinetics (PK), and antitumor activity as monotherapy and in combination with venetoclax in patients with relapsed or refractory (R/R) hematologic malignancies. Methods: In the monotherapy cohort (n=61), patients with hematologic malignancies received AZD5991 intravenously in escalating doses either once or twice weekly, following intrapatient dose escalation, on a 3-week cycle. In the combination cohort (n=17), patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) recei

APA, Harvard, Vancouver, ISO, and other styles

16

Wils, Leon J., Jos B. Poell, Arjen Brink, et al. "Elucidating the genetic landscape of oral leukoplakia to predict malignant transformation." Clinical Cancer Research, November 30, 2022. http://dx.doi.org/10.1158/1078-0432.ccr-22-2210.

Full text

Abstract:

Abstract Purpose: Oral leukoplakia is the most common oral potentially malignant disorder with an annual malignant transformation rate of 1-5%. Consequently, oral leukoplakia patients have a 30-50% lifetime risk to develop oral squamous cell carcinoma. Although risk factors for malignant transformation of oral leukoplakia have been investigated, no definitive risk stratification model has been proposed. Next generation sequencing can elucidate the genetic landscape of oral leukoplakia which may be used to predict the risk for malignant transformation. Experimental Design: We investigated a ret

APA, Harvard, Vancouver, ISO, and other styles

17

Gerber, David E., Claire R. Wynters, Tanushree Prasad, et al. "Development, review, and activation of thoracic oncology investigator-initiated trials." Clinical Cancer Research, January 17, 2025. https://doi.org/10.1158/1078-0432.ccr-24-3460.

Full text

Abstract:

Abstract Background: Investigator-initiated trials (IITs) may address important biological and clinical questions that may not be prioritized by pharmaceutical sponsors. However, little is known about the process by which IIT proposals are evaluated and activated. Methods: We performed a retrospective study of IIT concepts submitted through the Academic Thoracic Oncology Medical Investigators Consortium (ATOMIC), which comprises 13 institutions in the U.S. and Canada, from 2014 (consortium inception) to 2024. We compared approved and disapproved concepts using chi-squared tests, Fisher’s exact

APA, Harvard, Vancouver, ISO, and other styles

18

Lee, Chung-Han, Robert Motzer, Hamid Emamekhoo, et al. "Telaglenastat Plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 ENTRATA Trial." Clinical Cancer Research, May 16, 2022. http://dx.doi.org/10.1158/1078-0432.ccr-22-0061.

Full text

Abstract:

Abstract Purpose: Glutaminase is a key enzyme that supports elevated dependency of tumors on glutamine-dependent biosynthesis of metabolic intermediates. Dual targeting of glucose and glutamine metabolism by the mTOR inhibitor everolimus plus the oral glutaminase inhibitor telaglenastat showed preclinical synergistic anticancer effects which translated to encouraging safety and efficacy findings in a phase 1 trial of 2L+ renal cell carcinoma (RCC). This study evaluated telaglenastat plus everolimus (TelaE) versus placebo plus everolimus (PboE) in patients with advanced/metastatic RCC (mRCC) in

APA, Harvard, Vancouver, ISO, and other styles

19

Sugimoto, Akira, Shingo Matsumoto, Hibiki Udagawa, et al. "A large-scale prospective concordance study of plasma- and tissue-based next-generation targeted sequencing for advanced non-small cell lung cancer (LC-SCRUM-Liquid)." Clinical Cancer Research, October 6, 2022. http://dx.doi.org/10.1158/1078-0432.ccr-22-1749.

Full text

Abstract:

Abstract Purpose: We evaluated plasma cell-free DNA (cfDNA) and tissue-based sequencing concordance for comprehensive oncogenic driver detection in non-small cell lung cancer (NSCLC) using a large-scale prospective screening cohort (LC-SCRUM-Liquid). Methods: Blood samples were prospectively collected within four weeks of corresponding tumor tissue sampling from advanced NSCLC patients to investigate plasma cfDNA sequencing concordance for alterations in eight oncogenes (EGFR, KRAS, BRAF, HER2, MET, ALK, RET, and ROS1) compared to tissue-based next-generation targeted sequencing. Results: Pair

APA, Harvard, Vancouver, ISO, and other styles

20

Marmouset, Vincent, Justine Decroocq, Sylvain Garciaz, et al. "Therapy related myeloid neoplasms following PARP inhibitors: real-life experience." Clinical Cancer Research, October 6, 2022. http://dx.doi.org/10.1158/1078-0432.ccr-22-1622.

Full text

Abstract:

Abstract Purpose: To provide insights into the diagnosis and management of therapy-related myeloid neoplasms (t-MN) following PARP inhibitors (PARPi). Experimental Design: In a French cancer center, we identified and described the profiles of 13 t-MN diagnosed among 37 ovarian cancer (OC) patients referred to hematology consultation for cytopenia under PARPi. Next, we described these 13 t-MN post PARPi among 37 t-MN post OC according to PARPi exposure. Finally, we described 69 t-MN post PARPi in a national cohort. Results: From 2016 to 2021, cumulative incidence of t-MN was 3.5% (13/373) among

APA, Harvard, Vancouver, ISO, and other styles

21

Chen, Monica F., Soo-Ryum Yang, Jessica J. Tao, et al. "Tumor-agnostic genomic and clinical analysis of BRAF fusions identify actionable targets." Clinical Cancer Research, June 26, 2024. http://dx.doi.org/10.1158/1078-0432.ccr-23-3981.

Full text

Abstract:

Abstract Background: Even though BRAF fusions are increasingly detected in standard multigene next-generation sequencing panels, few reports have explored their structure and impact on clinical course. Patients/methods: We collected data from patients with BRAF fusion-positive cancers identified through a genotyping protocol of 97,024 samples. Fusions were characterized and reviewed for oncogenic potential (in-frame status, non-BRAF partner gene, intact BRAF kinase domain). Results: We found 241 BRAF fusion-positive tumors from 212 patients with 82 unique 5’ fusion partners spanning 52 histolo

APA, Harvard, Vancouver, ISO, and other styles

22

Boucher, Yves, Jessica M. Posada, Sonu Subudhi, et al. "Addition of losartan to FOLFIRINOX and chemoradiation reduces immunosuppression-associated genes, Tregs and FOXP3+ cancer cells in locally advanced pancreatic cancer." Clinical Cancer Research, February 7, 2023. http://dx.doi.org/10.1158/1078-0432.ccr-22-1630.

Full text

Abstract:

Abstract Purpose: Adding losartan (LOS) to FOLFIRINOX (FFX) chemotherapy followed by chemoradiation (CRT) resulted in 61% R0 surgical resection in our phase II trial in patients with locally advanced pancreatic cancer (LAPC). Here we identify potential mechanisms of benefit by assessing the effects of neoadjuvant losartan on the tumor microenvironment. Experimental Design: We performed a gene expression and immunofluorescence (IF) analysis using archived surgical samples from patients treated with LOS+FFX+CRT (NCT01821729), FFX+CRT (NCT01591733) or surgery upfront, without any neoadjuvant ther

APA, Harvard, Vancouver, ISO, and other styles

23

Hanna, Glenn J., Scott A. Roof, James Jabalee, et al. "Negative Predictive Value of Circulating Tumor Tissue Modified Viral (TTMV)-HPV DNA for HPV-driven Oropharyngeal Cancer Surveillance." Clinical Cancer Research, August 11, 2023. http://dx.doi.org/10.1158/1078-0432.ccr-23-1478.

Full text

Abstract:

Abstract Background: Human papillomavirus (HPV) is causally linked to oropharyngeal squamous cell carcinoma (OPSCC). Consensus guidelines recommend clinical exams and imaging in decreasing frequency as part of post-treatment surveillance for recurrence. Plasma tumor tissue modified viral (TTMV)-HPV DNA testing has emerged as a biomarker which can inform disease status during surveillance. Methods: This retrospective observational cohort study involved 543 patients who completed curative-intent therapy for HPV-associated OPSCC between February 2020 and January 2022 at 8 U.S. cancer care institu

APA, Harvard, Vancouver, ISO, and other styles

24

Song, Yuqin, Zhengming Jin, Zhi-Ming Li, et al. "Enhancer of zeste homolog 2 inhibitor SHR2554 in relapsed or refractory peripheral T-cell lymphoma: data from the first-in-human phase 1 study." Clinical Cancer Research, January 8, 2024. http://dx.doi.org/10.1158/1078-0432.ccr-23-2582.

Full text

Abstract:

Abstract Purpose: Patients with peripheral T-cell lymphomas (PTCLs) in the relapsed or refractory (r/r) setting have only a limited number of therapies available, and the prognosis is extremely poor. SHR2554 is an oral inhibitor against EZH2, a rational therapeutic target for lymphomas. Patients and Methods: This was a multicenter, 2-part, phase 1 study of SHR2554 in r/r mature lymphoid neoplasms. In part I, 350 mg twice daily was established as the recommended phase 2 dose (RP2D) based on the findings during dose-escalation and expansion; subsequently, selected lymphoma subtypes were recruite

APA, Harvard, Vancouver, ISO, and other styles

25

Elmacken, Mona, Helkha Peredo-Pinto, Cong Wang, et al. "FDA Approval Summary: Lisocabtagene Maraleucel for Second-Line Treatment of Large B-Cell Lymphoma." Clinical Cancer Research, February 7, 2024. http://dx.doi.org/10.1158/1078-0432.ccr-23-2967.

Full text

Abstract:

Abstract In June 2022, the FDA extended the indication for lisocabtagene maraleucel (liso-cel) to include adults with large B-lymphoma (LBCL) who have refractory disease or relapse within 12 months of first-line chemoimmunotherapy, as well as transplant-ineligible adults with refractory disease or relapse after first-line chemoimmunotherapy. Two clinical trials evaluating a single infusion of liso-cel preceded by lymphodepleting chemotherapy supported the second-line indications. TRANSFORM is a randomized, phase 3, open-label trial comparing liso-cel to standard second-line therapy, including

APA, Harvard, Vancouver, ISO, and other styles

26

Hernando-Calvo, Alberto, Richard D. Carvajal, Paul K. Paik та ін. "Phase I clinical trial of the bifunctional EGFR/TGF-β fusion protein ficerafusp alfa (BCA101) alone and in combination with pembrolizumab for advanced solid tumors". Clinical Cancer Research, 11 липня 2025. https://doi.org/10.1158/1078-0432.ccr-25-0100.

Full text

Abstract:

Abstract Purpose: To evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of ficerafusp alfa (BCA101), a first-in-class bifunctional protein targeting epidermal growth factor receptor (EGFR) and TGF-β, as monotherapy and in combination with pembrolizumab, in patients with advanced solid tumors. Patients and methods: At escalating doses in a parallel 3+3 design, patients with EGFR-driven advanced solid tumors received weekly intravenous ficerafusp alfa monotherapy (64-1500 mg) or in combination (240-1500 mg) with pembrolizumab (200 mg intravenously every 3 weeks). The primary o

APA, Harvard, Vancouver, ISO, and other styles

27

Hussain, Maha, Masha Kocherginsky, Neeraj Agarwal, et al. "Abiraterone, Olaparib, or Abiraterone + Olaparib in First-line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway)." Clinical Cancer Research, August 8, 2024. http://dx.doi.org/10.1158/1078-0432.ccr-24-1402.

Full text

Abstract:

Abstract Purpose: Deleterious germline/somatic homologous recombination-repair mutations (HRRm) are present in ~25% of metastatic castration resistant prostate cancer (mCRPC) patients. Preclinically, PARP-Inhibition demonstrated synergism with ARP-targeted therapy. This trial evaluated efficacy of ARP-Inhibitor versus PARP-Inhibitor versus combination as first-line therapy in mCRPC patients with HRRm. Patients and Methods: BRCAAway is a biomarker pre-selected, randomized, phase-2 trial. Patients with BRCA1/2 and/or ATM alterations were randomized 1:1:1 to Arm1: Abiraterone (1000mg)/prednisone

APA, Harvard, Vancouver, ISO, and other styles

28

Pietrantonio, Filippo, Paolo Manca, Sara Erika Bellomo, et al. "HER2 copy number and resistance mechanisms in patients with HER2-positive advanced gastric cancer receiving initial trastuzumab-based therapy in JACOB trial." Clinical Cancer Research, November 22, 2022. http://dx.doi.org/10.1158/1078-0432.ccr-22-2533.

Full text

Abstract:

Abstract Purpose: In JACOB trial, pertuzumab added to trastuzumab-chemotherapy did not significantly improve survival of patients with HER2-positive metastatic gastric cancer, despite 3.3 months increase versus placebo. HER2 copy number variation (CNV) and AMNESIA panel encompassing primary resistance alterations (KRAS/PIK3CA/MET mutations, KRAS/EGFR/MET amplifications) may improve patients’ selection for HER2 inhibition. Experimental design: In a post-hoc analysis of JACOB on 327 samples successfully sequenced by NGS (Oncomine Focus DNA), HER2 CNV, HER2 expression by IHC and AMNESIA were corr

APA, Harvard, Vancouver, ISO, and other styles

29

Antoniotti, Carlotta, Alessandra Boccaccino, Robert Seitz, et al. "An immune-related gene expression signature predicts benefit from adding atezolizumab to FOLFOXIRI plus bevacizumab in metastatic colorectal cancer." Clinical Cancer Research, April 6, 2023. http://dx.doi.org/10.1158/1078-0432.ccr-22-3878.

Full text

Abstract:

Abstract Background: AtezoTRIBE phase II randomized study demonstrated that adding atezolizumab to first-line FOLFOXIRI (5fluoruracil, oxaliplatin, irinotecan) plus bevacizumab prolongs progression-free survival (PFS) of metastatic colorectal cancer (mCRC) patients, with a modest benefit among proficient mismatch repair (pMMR). DetermaIO is an immune-related 27-gene expression signature able to predict benefit from immune-checkpoint inhibition in triple-negative breast cancer. In this analysis of AtezoTRIBE, we investigated the predictive impact of DetermaIO in mCRC. Methods: mCRC patients uns

APA, Harvard, Vancouver, ISO, and other styles

30

Lacouture, Mario E., Elena Goleva, Neil Shah, et al. "Immunologic Profiling of Immune-Related Cutaneous Adverse Events with Checkpoint Inhibitors Reveals Polarized Actionable Pathways." Clinical Cancer Research, April 23, 2024. http://dx.doi.org/10.1158/1078-0432.ccr-23-3431.

Full text

Abstract:

Abstract Purpose: Immune-related cutaneous adverse events (ircAEs) occur in ≥50% of patients treated with checkpoint inhibitors (CPI), but mechanisms are poorly understood. Experimental Design: Phenotyping/biomarker analyses were conducted in 200 patients on CPIs (139 with ircAEs, 61 without, control) to characterize their clinical presentation and immunologic endotypes. Cytokines were evaluated in skin biopsies, skin tape strip (STS) extracts and plasma using real-time PCR and Meso Scale Discovery multiplex cytokine assays. Results: Eight ircAE phenotypes were identified: pruritus (26%), macu

APA, Harvard, Vancouver, ISO, and other styles

31

Loree, Jonathan M., Emma Titmuss, James T. Topham, et al. "Plasma versus tissue tumor mutational burden as biomarkers of durvalumab plus tremelimumab response in patients with metastatic colorectal cancer in the CO.26 trial." Clinical Cancer Research, May 10, 2024. http://dx.doi.org/10.1158/1078-0432.ccr-24-0268.

Full text

Abstract:

Abstract Purpose: Tissue derived tumor mutation burden (TMB) of ≥10 mutations/Mb is a histology agnostic biomarker for the immune checkpoint inhibitor (ICI) pembrolizumab. However, the dataset on which this was validated lacked colorectal cancers (CRCs), and there is limited evidence for immunotherapy benefit in CRC using this threshold. Patients and Methods: CO.26 was a randomized phase II study of 180 patients comparing durvalumab and tremelimumab (D+T, n=119 patients) versus best supportive care (BSC, n=61 patients). ctDNA sequencing was available for 168 patients (n=118 D+T, n=50), of whic

APA, Harvard, Vancouver, ISO, and other styles

32

Nieto, Yago, Jeremy Ramdial, Benigno Valdez, et al. "Enhancement Of High-Dose Chemotherapy and Autologous SCT with the PARP Inhibitor Olaparib for Refractory Lymphoma." Clinical Cancer Research, January 13, 2025. https://doi.org/10.1158/1078-0432.ccr-24-3544.

Full text

Abstract:

Abstract PURPOSE: More active high-dose chemotherapy (HDC) regimens are needed for autologous stem-cell transplantation (ASCT) for refractory lymphomas. Seeking HDC enhancement with a poly(ADP-ribose) polymerase (PARP) inhibitor, we observed marked synergy between olaparib and vorinostat/gemcitabine/busulfan/melphalan (GemBuMel) against lymphoma cell lines, mediated by inhibition of DNA damage repair. Our preclinical work led us to clinically study olaparib/vorinostat/GemBuMel with ASCT. METHODS: Patients ages 15-65 with refractory lymphoma and adequate end-organ function were eligible for thi

APA, Harvard, Vancouver, ISO, and other styles

33

Dolomatov, S.I., та W. Zukow. "Эпигенетика почек = Kidneys epigenetics". 7 липня 2019. https://doi.org/10.5281/zenodo.3270754.

Full text

Abstract:

<strong>Dolomatov S.I., Zukow W. </strong><strong>Эпигенетика почек</strong><strong> = Kidney</strong><strong>s</strong><strong> epigenetics</strong><strong>. </strong><strong>RSW. Radom,</strong><strong> 144 </strong><strong>p. ISBN </strong><strong>9780359774524</strong><strong>.</strong><strong> DOI </strong><strong>http://dx.doi.org/10.5281/zenodo.3270699</strong><strong> PBN Poland </strong><strong>https://pbn.nauka.gov.pl/sedno-webapp/works/917606</strong>           <strong>Radomska Szkoła Wyższa w Radomiu, Radom, Poland</strong>         &nbsp

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!